Earnings Releases

REVIVA PHARMACEUTICALS HOLDINGS, INC. reported financial results for the full year ended December 31, 2025.

“Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights”

Fathom Holdings Inc. reported the full year ended December 31, 2025 results: revenue $420.5 million, net income $20.3 million, EPS $0.72 per share.

“the fourth quarter and full year ended December 31, 2025. “During 2025, we continued executing our strategy and strengthening the foundation of the Fathom platform, generating $420 million in revenue, representing 25% year-over-year growth, while total transactions increased nearly 15%,” said Marco Fregenal, President and Chief Executive Officer of Fathom Holdings.”

Fathom Holdings Inc. reported the fourth quarter ended December 31, 2025 results: revenue $90.6 million, net income $6.7 million, EPS $0.21 per share.

“growth, improved profitability, and greater operating leverage over time.” Fourth Quarter 2025 Financial Highlights – March Update • Fathom’s total revenue decreased 1.2% to $90.6 million for the fourth quarter of 2025, down from $91.7 million in the fourth quarter of 2024. • B rokerage revenue decreased by 3.2% to $84.9 million for the fourth quarter of 2025,”

Lantern Pharma Inc. reported financial results for the fiscal year and fourth quarter ended December 31, 2025.

“On March 30, 2026, Lantern Pharma Inc. (the “Company”) will issue a press release announcing its financial results for the fiscal year and fourth quarter ended December 31, 2025.”

Unicycive Therapeutics, Inc. reported the full year ended December 31, 2025 results: net income $26.6 million, EPS $1.67 per share of common stock.

“Net loss attributable to common stockholders for the year ended December 31, 2025 was $26.6 million, or $1.67 per share of common stock, compared to a net loss attributable to common stockholders of $37.8 million, or $5.65 per share of common stock for the same period in 2024.”

SPRUCE POWER HOLDING CORP reported the full-year ended December 31, 2025 results: net income $26.0 million.

“Net loss attributable to stockholders of $6.9 million and $26.0 million for the quarter and year, respectively, compared to net loss attributable to stockholders of $5.9 million and $70.5 million for the year-earlier periods”

SPRUCE POWER HOLDING CORP reported the fourth quarter ended December 31, 2025 results: revenue $24.0 million, net income $6.9 million, EPS $0.38 per share.

“Consolidated Financial Results Revenues totaled $24.0 million for the fourth quarter of 2025 , compared with $20.2 million for the fourth quarter of 2024. The year-over-year increase was primarily due to the November 2024 acquisition of a residential solar portfolio from NJR Clean Energy Ventures ("NJR") and improved solar renewable energy credits ("SRECs") revenue. The Spruce PRO service agreement signed with ADT in December 2024 also contributed to growth. Total operating expenses were $21.8 million for the fourth quarter of 2025, compared to $26.7 million for the fourth quarter of 2024. The year-over-year decline in operating expense is attributed primarily to a decrease in operations and maintenance costs and ongoing cost management efforts. Core Operating Expenses, which includes both SG&A expenses and O&M expenses was $14.9 million in the aggregate for the fourth quarter of 2025, down from $20.7 million in the year-earlier period. This includes $13.0 million of SG&A expenses and”

Lulu's Fashion Lounge Holdings, Inc. updated its fourth quarter and fiscal year ended December 28, 2025 guidance (initiated).

“On March 30, 2026, Lulu’s Fashion Lounge Holdings, Inc. (“Lulus”) issued a press release containing Lulus’ financial results for its fourth quarter and fiscal year ended December 28, 2025 and issued its financial outlook for the fiscal year ending January 3, 2027.”

Aptera Motors Corp reported financial results for for the fourth quarter and full year ended December 31, 2025.

“Aptera Motors Reports Fourth Quarter and Full Year 2025 Financial Results ● Reports Q4 2025 GAAP Net Loss of $15.5 Million and Full Year Net Loss of $43.9 Million ● Calculates Q4 2025 Adjusted Net Loss of $8.7 Million (Non-GAAP) and Full Year Adjusted Net Loss of $18.5 Million (Non-GAAP) ● Recognized $4.2 Million in Other Income for the Full Year, primarily from California Energy Commission Grant ● Ended Year with $9.6 Million in Cash and Cash Equivalents”

Jasper Therapeutics, Inc. reported the quarter and year ended December 31, 2025 results: net income a net loss of $9.1 million and $75.8 million, or basic and diluted net loss per share attributable to common stockholder, EPS $0.32 and $3.95.

“Jasper reported a net loss of $9.1 million and $75.8 million, or basic and diluted net loss per share attributable to common stockholders of $0.32 and $3.95, for the three months and year ended December 31, 2025, respectively.”

DeFi Development Corp. reported Fiscal Year 2025 results: revenue 442% revenue growth.

“DeFi Development Corp. Reports +442% Revenue Growth For FY 2025”

Veradermics, Inc reported financial results for the fourth quarter and year ended December 31, 2025.

“On March 30, 2026, Veradermics, Incorporated issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2025.”

Sensei Biotherapeutics, Inc. reported the full year ended December 31, 2025 results: net income Net loss was $21.1 million, or $(16.72) per basic and diluted share, EPS $(16.72) per basic and diluted share.

“breast cancer, with additional opportunities in ovarian and lung cancer.” Full Year 2025 Financial Results Cash Position: Cash, cash equivalents and marketable securities were $21.2 million as of December 31, 2025 as compared to $41.3 million as of December 31, 2024. Research and Development (R&D) Expenses: R&D expenses were $11.0 million for the year ended December”

Functional Brands Inc. reported financial results for fourth quarter and full-year ended December 31, 2025.

“On March 30, 2026, Functional Brands, Inc. (the “Company”), issued a press release regarding the Company’s financial results for its fourth fiscal quarter and fiscal year ended December 31, 2025, and certain recent corporate developments.”

AEON Biopharma, Inc. reported financial results for the year ended December 31, 2025.

“On March 30, 2026, AEON Biopharma, Inc. (the “Company” or “AEON”) announced financial results for the year ended December 31, 2025.”

XBP Global Holdings, Inc. reported the fourth quarter ended December 31, 2025 results: revenue $207.0 million.

“Fourth Quarter 2025 Highlights ● Revenue totaled $207.0 million, a decline of 15.1% year-over-year on a pro forma basis 4 ● Gross margin was 22.7%, a 110 basis point increase year-over-year on a pro forma basis 4 ● Pro Forma Normalized EBITDA 3 of $19.2 million, a decrease of 35.0% year-over-year 4 ● Closed $60.2 million of new TCV, a 53.2% increase year-over-year and 68.4% above the previous four quarter average 4,5 ● Closed $34.8 million of new ACV, a 37.7% increase year-over-year and 46.7% above the previous four quarter average 4,5”

XBP Global Holdings, Inc. reported the fiscal year ended December 31, 2025 results: revenue $791.0 million, net income $1.1 billion.

“Full Year 2025 Highlights ● Reported revenue 1 totaled $791.0 million, a decline of 9.4% year-over-year ● Gross margin on a reported basis was 21.7%, a 10 basis point increase year-over-year ● Combined Pro Forma Revenue 2 totaled $879.6 million, a decline of 13.6% year-over-year ● Pro Forma Gross Margin 2 was 21.9%, a 30 basis point increase year-over-year ● GAAP net income of $1.1 billion, compared to a Net Loss of $215.2 million the prior year ● Pro Forma Normalized EBITDA 2,3 of $90.2 million, a decrease of 13.7% year-over-year”

Eikon Therapeutics, Inc. reported fourth quarter and full year ended December 31, 2025 results: net income Net loss attributable to common stockholders was $79.7 million for the fourth quarter of 2025.

“On March 30, 2026, Eikon Therapeutics, Inc. issued a press release announcing clinical and corporate updates and its financial results for the three months and full year ended December 31, 2025”

Neumora Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2025.

“On March 30, 2026, Neumora Therapeutics, Inc. (“Neumora” or the “Company”) announced its financial results for the fourth quarter and full year ended December 31, 2025.”

Lexeo Therapeutics, Inc. reported financial results for the fourth quarter and full year 2025.

“On March 30, 2026, Lexeo Therapeutics, Inc. (the “ Company ”) issued a press release announcing business highlights and its financial results for the three and twelve months ended December 31, 2025.”

Falcon's Beyond Global, Inc. reported fiscal year ended December 31, 2025 results: revenue $14.9 million, net income $6.3 million.

“Falcon's Beyond reported annual revenue of $14.9 million”

Falcon's Beyond Global, Inc. reported fourth quarter 2025 results: revenue $6.6 million.

“Falcon's Beyond reported fourth quarter revenue of $6.6 million”

USA Rare Earth, Inc. reported financial results for the fourth quarter and year ended December 31, 2025.

“On March 30, 2026, USA Rare Earth, Inc. (the “Company”) issued an earnings press release announcing its financial results for the fourth quarter and year ended December 31, 2025.”

Innventure, Inc. reported financial results for the quarter and year ended December 31, 2025.

“On March 30, 2026, Innventure, Inc. (the “Company”) issued a press release, attached hereto as Exhibit 99.1 and incorporated herein by reference, announcing the Company’s financial results for the fiscal year ended December 31, 2025, and certain other information.”

Terrestrial Energy Inc. /DE/ reported the fourth quarter and full year ended December 31, 2025 results: net income $28 million Net Loss.

“The Company reports a $28 million Net Loss for 2025”

Bicara Therapeutics Inc. reported the fourth quarter and full year ended December 31, 2025 results: net income Net loss totaled $37.4 million and $138.0 million for the fourth quarter and full year ended December 31, 2025, respecti.

“On March 30, 2026, Bicara Therapeutics Inc. (the "Company") issued a press release announcing its financial results and business highlights for the fiscal year and quarter ended December 31, 2025.”

Aktis Oncology, Inc. reported the year ended December 31, 2025 results: revenue $6.5 million.

“the January 2026 IPO. The Company believes that the pro forma as adjusted cash position will fund its operations into 2029. • Collaboration revenue: Collaboration revenue was $6.5 million for the year ended December 31, 2025, compared to $1.5 million for the year ended December 31, 2024. The increase was attributable to revenue recognized under the Company’s”

Fermi Inc. reported financial results for the period from January 10, 2025 (Inception) through December 31, 2025.

“On March 30, 2026, Fermi Inc. (the “Company”) issued its shareholder letter (the “Shareholder Letter”) announcing its financial results for the period from January 10, 2025 (Inception) through December 31, 2025.”

ARKO Petroleum Corp. reported the full year ended December 31, 2025 results: net income $32.7 million.

“For the year, net income was $32.7 million compared to $40.2 million.”

ARKO Petroleum Corp. reported the fourth quarter ended December 31, 2025 results: net income $8.1 million.

“Net income for the quarter increased to $8.1 million compared to $7.5 million.”

TherapeuticsMD, Inc. reported the full year ended December 31, 2025 results: revenue $3.0 million, net income $(0.7) million, EPS $(0.06) per basic and diluted common share.

“or $(0.20) per basic and diluted common share, for 2024. License Revenues from Continuing Operations ● License revenue, primarily from the Mayne License Agreement, totaled $3.0 million during the year ended December 31, 2025, an increase of $1.3 million, or 71.6%, compared to $1.8 million in license revenue during the year ended December 31, 2024. The increase”

Soluna Holdings, Inc reported financial results for the three months and fiscal year ended December 31, 2025.

“On March 30, 2026, Soluna Holdings, Inc. (the “Company”) issued a press release announcing its financial results for the three months and fiscal year ended December 31, 2025.”

CVD EQUIPMENT CORP reported financial results for the fourth quarter and fiscal year ended December 31, 2025.

“On March 30, 2026, the Company issued a press release announcing its results of operations for the fourth quarter and fiscal year ended December 31, 2025.”

PROGRESS SOFTWARE CORP /MA reported its fiscal first quarter ended February 28, 2026 results: revenue $247,799, net income $22,813, EPS $0.53.

“Three Months Ended GAAP Non-GAAP (in thousands, except percentages and per share amounts) February 28, 2026 February 28, 2025 % Change February 28, 2026 February 28, 2025 % Change Revenue $ 247,799 $ 238,015 4 % $ 247,799 $ 238,015 4 % Income from operations $ 46,465 $ 32,426 43 % $ 102,185 $ 93,595 9 % Operating margin 19 % 14 % 500 bps 41 % 39 % 200 bps Net income $ 22,813 $ 10,946 108 % $ 68,300 $ 58,995 16 % Diluted earnings per share $ 0.53 $ 0.24 121 % $ 1.60 $ 1.31 22 %”

SYSCO CORP updated its third quarter of fiscal 2026, which ended on March 28, 2026 guidance (reaffirmed).

“On March 30, 2026, Sysco provided supplemental information regarding the transactions described in Item 7.01 below in a presentation to analysts and investors, which also included certain information regarding Sysco’s results of operations for its third quarter of fiscal 2026 and for its fiscal 2026, which is ending on June 27, 2026”

UNITED GUARDIAN INC reported FY 2025 results: revenue $10,545,468, net income $2,105,738, EPS $0.46 per share.

“United-Guardian Reports 2025 Financial Results HAUPPAUGE, N.Y., March 27, 2026 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (NASDAQ:UG) reported that net sales and net income for FY 2025 decreased compared to FY 2024. Net sales for the year decreased by 13% from $12,181,971 in 2024 to $10,545,468 in 2025, generating net income of $3,250,875 ($0.71 per share) in 2024 compared to $2,105,738 ($0.46 per share) in 2025.”

WORTHINGTON ENTERPRISES, INC. reported the third quarter of fiscal 2026 ended February 28, 2026 results: net income $45,120.

“adjusted EBITDA for the TTM ended February 28, 2026 and 2025. Third Second First Fourth Quarter Quarter Quarter Quarter (In thousands) 2026 2026 2026 2025 Net earnings (GAAP) $ 45,120 $ 27,029 $ 34,821 $ 3,614 Plus: Net loss attributable to noncontrolling interest 343 299 327 263 Net earnings attributable to controlling interest 45,463 27,328 35,148 3,877”

CARNIVAL PLC reported first quarter 2026 results: revenue $6.2 billion, net income $258 million, EPS $0.19.

“Carnival Corporation & plc (NYSE/LSE: CCL; NYSE: CUK) announced financial results for the first quarter 2026 and provided an updated outlook. • D iluted EPS of $0.19 and adjusted EPS 1 of $0.20, up 50 percent compared to the prior year. • Record revenues 2 of $6.2 billion, gross margin yields up nearly 10 percent and record net yields 1,2 (in constant currency), outperforming guidance on strong close-in demand.”

AIxCrypto Holdings, Inc. reported financial results for the fiscal year ended December 31, 2025.

“On March 24, 2026, the Company issued a press release announcing its financial and operational results for the fiscal year ended December 31, 2025, and an investor webcast that occurred on March 24, 2026 to discuss such results and update shareholders on general corporate developments.”

Lifeloc Technologies, Inc reported year ended December 31, 2025 results: revenue $9.027 million, net income ($2.470) million, EPS ($0.90) per diluted share.

“devices, has announced financial results for the 2025 fiscal year ended December 31, 2025. 2025 Financial Highlights Lifeloc Technologies reported revenue growth of 6% to $9.027 million for 2025, compared to net revenue of $8.538 million for 2024. We realized a net loss of ($2.470) million , or ($0.90) per diluted share for the year ending December 31, 2025”

LogicMark, Inc. reported the year ended December 31, 2025 results: revenue $11.4 million, net income $7.5 million, EPS $13.06.

“December 31, 2025. Fourth Quarter and Full Year 2025 Financial Highlights ● Revenue: Fourth-quarter revenue increased 36% to $3.1 million. Full-year revenue increased 15% to $11.4 million. Revenue has increased year-over-year in six of the last seven quarters. ● Gross margin: Fourth quarter gross margin increased to 69.8%. Full-year gross margin remained strong at”

LogicMark, Inc. reported the fourth quarter ended December 31, 2025 results: revenue $3.1 million, net income $1.6 million, EPS $1.96.

“results for the fourth quarter and year ended December 31, 2025. Fourth Quarter and Full Year 2025 Financial Highlights ● Revenue: Fourth-quarter revenue increased 36% to $3.1 million. Full-year revenue increased 15% to $11.4 million. Revenue has increased year-over-year in six of the last seven quarters. ● Gross margin: Fourth quarter gross margin increased”

INTENSITY THERAPEUTICS, INC. reported financial results for the year ended December 31, 2025.

“On March 27, 2026, Intensity Therapeutics, Inc. (the “Company”) released its financial results for the year ended December 31, 2025.”

Entera Bio Ltd. reported financial results for the year ended December 31, 2025.

“On March 27, 2026, Entera Bio Ltd., a company organized under the laws of the State of Israel (“we,” “us,” “our” or the “Company”), issued a press release announcing its financial results for the year ended December 31, 2025 and business updates.”

LM FUNDING AMERICA, INC. reported Three and Twelve Months ended December 31, 2025 results: revenue $2.4 million, net income Net loss of $17.9 million.

“it by reference. --- EX-99.1 (EX-99.1) --- EX-99.1 LM Funding America, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results - Fourth quarter revenue of $2.4 million, up 8.7% sequentially and 19.2% year-over-year TAMPA, FL, March 27, 2026—LM Funding America, Inc. (NASDAQ: LMFA) (“LM Funding” or the “Company”), a Bitcoin treasury and mining”

iANTHUS CAPITAL HOLDINGS, INC. reported the fiscal year ended December 31, 2025 results: revenue $144.0 million, net income $40.2 million, EPS less than $0.01 per share.

“reported in accordance with U.S. generally accepted accounting principles (“GAAP”). All currency is expressed in U.S. dollars. Fiscal Year 2025 Financial Highlights • Revenue of $144.0 million, a decrease of 14.1% from the prior year. • Gross profit of $65.7 million, a decrease of 12.5% from the prior year. • Gross margin of 45.6%, reflecting an increase of 80 bps from”

Monopar Therapeutics reported year ended December 31, 2025 results: net income Net loss for the year ended December 31, 2025, was $13.7 million, or $1.85 per share.

“Net loss for the year ended December 31, 2025, was $13.7 million, or $1.85 per share”

Monopar Therapeutics reported fourth quarter and full year ended December 31, 2025 results: net income Net loss for the fourth quarter of 2025 was $5.2 million, or $0.61 per share.

“the fourth quarter and full-year 2025 financial results”

HYDROFARM HOLDINGS GROUP, INC. reported the fourth quarter and fiscal year ended December 31, 2025 results: revenue $25.1 million, net income $242.2 million, EPS $(51.89) per diluted share.

“Net sales in the fourth quarter of 2025 decreased 32.7% to $25.1 million compared to $37.3 million in the prior year period. This was primarily due to a 27.3% decline in volume/mix of products sold primarily related to industry oversupply, and a 5.6% decrease in price. Gross Profit increased to $2.1 million, or 8.5% of net sales, compared to $1.8 million, or 4.9% of net sales, in the prior year period. Adjusted Gross Profit (1) increased to $3.9 million, or 15.4% of net sales, compared to $3.6 million, or 9.6% of net sales, in the prior year period. Gross Profit, Adjusted Gross Profit (1) , Gross Profit Margin, and Adjusted Gross Profit Margin (1) improved as a result of higher sales of proprietary brands and improved productivity. These increases more than offset the impact of lower net sales. Selling, general and administrative (“SG&A”) expense was $9.6 million, compared to $17.0 million in the prior year period, and Adjusted SG&A (1) expense was $8.8 million compared to $10.8 millio”

BioXcel Therapeutics, Inc. reported financial results for for the three months and year ended December 31, 2025.

“On March 27, 2026, BioXcel Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months and year ended December 31, 2025 and provided a business update.”